Enveda Names Christopher Porter SVP of Clinical Operations

Enveda has appointed Christopher K. Porter as Senior Vice President of Clinical Operations, adding an experienced drug-development executive as the privately held biotechnology company advances multiple programs into the clinic.

Porter joins Enveda as it expands its clinical pipeline and builds internal infrastructure to manage late-stage development. The company, founded in 2019, uses artificial intelligence to identify potential drug candidates derived from compounds found in nature.

In his new role, Porter will oversee clinical operations across Enveda’s portfolio of development-stage assets. The company has recently received regulatory clearance to initiate clinical trials for at least one inflammatory disease candidate.

Porter was most recently vice president of development strategy and innovation at Theravance Biopharma, where he led operational changes across several late-stage clinical programs involving global trials. Earlier in his career, he co-founded contract research organization Clinipace Worldwide, serving as president, chief operating officer, and general counsel, and helping grow the firm’s international footprint.

Enveda has raised several rounds of private financing over the past few years, including a Series D round completed in 2025. Following that fundraising, investors valued the company at more than $1 billion, according to prior disclosures.